背景:关于脑淀粉样血管病(CAA)的波士顿标准v2.0纳入了非出血性成像标志物。其在认知障碍患者中的患病率和意义仍不确定。
方法:我们研究了622名记忆门诊患者,这些患者具有可用的磁共振成像(MRI)和脑脊液(CSF)生物标志物。两名评估者评估了非出血标志物,我们通过多变量分析探讨了它们与临床特征的关联.
结果:大多数患者有轻度认知障碍;中位年龄为71岁,50%为女性。使用v2.0标准,可能或可能的CAA从75例增加到383例。68%的样本有非出血性CAA标记,与年龄独立相关(比值比[OR]=1.04,95%置信区间[CI]=1.01-1.07),女性(OR=1.68,95%CI=1.11-2.54),出血性CAA标志物(OR=2.11,95%CI=1.02-4.35)。
结论:记忆诊所队列中三分之二的患者具有非出血性CAA标志物,增加符合v2.0CAA标准的患者数量。纵向方法应该探索这些标记的含义,尤其是这个人群的出血风险。
结论:更新的波士顿脑淀粉样血管病(CAA)标准现在包括非出血性标志物。非出血性CAA标志物在记忆门诊患者中的患病率未知。我们的记忆诊所中有三分之二的患者表现出非出血性CAA标志物。这些标记的存在与年龄有关,女性性别,和出血性CAA标志物。出现这些类型标志物的患者的出血风险尚不清楚。
The Boston criteria v2.0 for cerebral amyloid angiopathy (CAA) incorporated non-hemorrhagic imaging markers. Their prevalence and significance in patients with cognitive impairment remain uncertain.
We studied 622 memory clinic patients with available magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers. Two raters assessed non-hemorrhagic markers, and we explored their association with clinical characteristics through multivariate analyses.
Most patients had mild cognitive impairment; median age was 71 years and 50% were female. Using the v2.0 criteria, possible or probable CAA increased from 75 to 383 patients. Sixty-eight percent of the sample had non-hemorrhagic CAA markers, which were independently associated with age (odds ratio [OR] = 1.04, 95% confidence interval [CI] = 1.01-1.07), female sex (OR = 1.68, 95% CI = 1.11-2.54), and hemorrhagic CAA markers (OR = 2.11, 95% CI = 1.02-4.35).
Two-thirds of patients from a memory clinic cohort had non-hemorrhagic CAA markers, increasing the number of patients meeting the v2.0 CAA criteria. Longitudinal approaches should explore the implications of these markers, particularly the hemorrhagic risk in this population.
The updated Boston criteria for cerebral amyloid angiopathy (CAA) now include non-hemorrhagic markers. The prevalence of non-hemorrhagic CAA markers in memory clinic patients is unknown. Two-thirds of patients in our memory clinic presented non-hemorrhagic CAA markers. The presence of these markers was associated with age, female sex, and hemorrhagic CAA markers. The hemorrhagic risk of patients presenting these type of markers remains unclear.